John Libbey Eurotext

Journal de Pharmacie Clinique

Highlights of the 2017 ISPOR Volume 36, issue 3, Septembre 2017

Figures

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
  • Figure 6
  • Figure 7

Tables

Authors
1 Pôle information médicale, évaluation, recherche, Unité d’évaluation médico-économique, Hospices civils de Lyon, Lyon, France ; Université Claude Bernard Lyon 1, Hesper EA 7425, Lyon, France
2 Unité de recherche médico-économique, CHU de Montpellier, Montpellier, France
3 Service pharmacie, CHU Nîmes, France ; EA2415 Institut universitaire de recherche clinique, Montpellier, France
4 Direction des achats, CHU Toulouse, Hôtel-Dieu, Toulouse, France
5 Pôle pharmacie, Site Groupe Hospitalier Sud, CHU Bordeaux, Bordeaux, France
6 ECEVE, UMR 1123, URCEco Ile de France Hôpital de l’Hôtel-Dieu, Paris, France
7 Hôpital Henri Mondor, AP-HP, Service santé publique, Créteil, France
8 Service pharmacie, Hôpital Antoine Béclère, GH HUPS, AP-HP, Clamart, France
9 Pôle pharmacie, Grand hôpital de l’Est francilien, Meaux, France
10 Service pharmacie, CHU Charles Nicolle, Rouen, France
* Tirés à part
  • Key words: market access, biosimilars, oncology, cost effectiveness
  • DOI : 10.1684/jpc.2017.0364
  • Page(s) : 169-82
  • Published in: 2017

The 22nd ISPOR (International society for phamacoeconomics and outcomes research) conference was held in Boston from May 20 to 24, 2017. A group of pharmacists, physicians and health economists attended the conference and reported some of the highlights and most striking points of this professionnal event. Market access is a domain that is developing and requires varied cooperations between payers, suppliers and users. This paper reports and explains some methods and economic evaluation tools that can be used, illustrated with concrete examples, such as the biosimilars or the medicine in oncology. It shows that a holistic approach is necessary to facilitate or not the access of innovative medicines and that the different schemes reported here are, however, highly dependent on the model of health of the considered geographical zone or on the given country.